Chemed (CHE) Receivables (2009 - 2026)

Chemed has reported Receivables for 18 years, with the latest figure at $215.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 25.03% year-over-year to $215.5 million; the trailing twelve-month figure through Mar 2026 stood at $215.5 million (down 25.03% YoY), and the FY2025 full-year result was $191.2 million, up 6.26% from the prior year.
• Receivables for Q1 2026 stood at $215.5 million, up from $191.2 million in the prior quarter.
• The five-year high for Receivables was $287.4 million in Q1 2025, with the low at $117.3 million in Q1 2022.
• Average Receivables over 5 years is $176.3 million, with a median of $180.0 million recorded in 2024.
• Year-over-year, Receivables surged 60.22% in 2025 and declined 25.03% in 2026.
• Tracing CHE's Receivables over 5 years: stood at $141.2 million in 2022, then grew by 29.7% to $183.2 million in 2023, then decreased by 1.76% to $180.0 million in 2024, then gained by 6.26% to $191.2 million in 2025, then rose by 12.68% to $215.5 million in 2026.
• The last three Receivables figures came in at $215.5 million (Q1 2026), $191.2 million (Q4 2025), and $223.7 million (Q3 2025), per Business Quant data.

Peer Comparison